Aclaris hammered as hair loss drug flops in PhII, days after FDA took issue with Eskata ads

The topical treatment for alopecia areata that Aclaris Therapeutics licensed from Rigel Pharma has failed a mid-stage study, leaving the company with a drug that seems to have caused no harm but no benefit either.